Table 4.
Clinical and biochemical differences between autoimmune and unspecified hypothyroidism.
| Autoimmune (n = 51) | Unspecified Hypothyroidism (n = 41) | p Value | |
|---|---|---|---|
| Age (years) | 32 (31–41) | 37 (32–50) | 0.36 |
| BMI (kg/m2) | 27.1 (25.3–33) | 26.9 (24.1–31.4) | 0.86 |
| Doses of levothyroxine for thyroid profile normalization (mg/day) | 100 (50–125) | 75 (50–150) | 0.07 |
| TSH before therapy (mIU/L) | 19.8 (7.6–43.5) | 17.9 (8.9–52.9) | 0.26 |
| TSH at treatment (mIU/L) | 1.8 (1.3–3.9) | 1.65 (1.0–3.6) | 0.13 |
| FT4 before therapy (pg/mL) | 0.16 (0.14–0.52) | 0.64 (0.32–1.2) | 0.02 * |
| FT4 at treatment (pg/mL) | 1.01 (0.94–1.2) | 1.1 (0.99–1.19) | 0.47 |
| Thyroid Peroxidase Antibodies (IU/mL) | 82 (43–93) | 5.8 (3.2–30.1) | 0.001 * |
| Thyroglobulin antibodies (IU/mL) | 25 (8.9–36.7) | 0.5 (0.3–1.4) | 0.003 * |
| FSS score before levothyroxine | 32 (15–48) | 31 (30–47) | 0.15 |
| FSS score at treatment | 24 (16–32) | 21 (18–29) | 0.09 |
Quantitative variables were reported as median and interquartile range. BMI: body mass index; TSH: thyroid stimulating hormone; FT4: free thyroxine; FSS: fatigue severity scale. * p > 0.05 = statistical significance.